Skip to main content
Log in

Neuroprotectant effects of LY 274614, a structurally novel systemically active competitive NMDA receptor antagonist

  • Full Papers
  • Published:
Journal of Neural Transmission / General Section JNT Aims and scope Submit manuscript

Summary

Antagonists for the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor may have therapeutic potential as neuroprotectant agents in conditions of neuronal degeneration that include brain ischemia, Huntington's chorea, and Alzheimer's disease. Here we have investigated the pharmacological actions of LY 274614, a structurally novel competitive NMDA receptor antagonist, for pharmacological selectivity and neuroprotectant effects following systemic administration. LY 274614 potently displaced NMDA receptor ([3H]CGS19755) binding (IC50=58.8±10.3 nM), but had no appreciable affinity at [3H]AMPA or [3H]kainate receptor sites at up to 10,000 nM. NMDA-induced convulsions in neonatal rats or NMDA-induced lethality in mice are potently and selectively antagonized by i.p. or p.o. LY 274614. Oral doses showed a delayed but prolonged duration of effect. In adult rats, the neuro-degenerative effects (loss of choline acetyltransferase activity) following the intrastriatal infusions of NMDA or quinolinate, but not kainate, were prevented by LY 274614 (2.5 to 20mg/kg i.p.). LY 274614 is an effective neuroprotectant agent against NMDA receptor-induced toxicity when administered systemically and is a promising therapeutic agent for conditions where glutamate plays a role in the pathology of neuronal degeneration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aebischer B, Frey P, Haerter H-P, Herrling PL, Mueller W, Olverman JH, Watkins JC (1989) Synthesis and NMDA antagonist properties of the enantiomers of 4-(3-phosphonopropyl)piperazine-2-carboxylic acid (CPP) and of the unsaturated analogue (E)-4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic acid (CPPene). Helv Chim Acta 72: 1043–1051

    Google Scholar 

  • Bennet JP Jr (1978) Methods in binding studies. In: Yamamura HI, Enna SJ, Kuhar MJ (eds) Neurotransmitter receptor binding, 1st edn. Raven Press, New York, pp 57–90

    Google Scholar 

  • Chandra V, Kokmen E, Schoenberg BS, Beard CM (1989) Head trauma with loss of consciousness as a risk for Alzheimer's disease. Neurology 39: 1576–1578

    Google Scholar 

  • Choi DW (1988) Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemie damage. Trends Neurosci 11: 465–469

    Google Scholar 

  • Choi DW, Rothman SM (1990) The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci 13: 171–182

    Google Scholar 

  • Collingridge GL, Lester RAJ (1989) Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol Rev 40: 143–210

    Google Scholar 

  • Faden AI, Demediuk P, Panter SS, Vink R (1989) The role of excitatory amino acids and NMDA receptors in traumatic brain inury. Science 244: 798–800

    Google Scholar 

  • Faden AI, Ellison JA, Noble LJ (1990) Effects of competitive and non-competitive NMDA receptor antagonists in spinal cord injury. Eur J Pharmacol 175: 165–174

    Google Scholar 

  • Fagg GE, Olpe H-R, Pozza MF, Baud J, Steinmann M, Schmutz M, Portet C, Baumann P, Thedinga K, Bittiger H, Allgeier H, Heckendorn R, Angst C, Brundish D, Dingwall JG (1990) CGP37849 and CGP39551: novel and potent competitive N-methyl-D-aspartate receptor antagonists with oral activity. Br J Pharmacol 99: 791–797

    Google Scholar 

  • Ferkany JW, Kyle DJ, Willets J, Rzeszotarski WJ, Guzewska ME, Ellenberger SR, Jones SM, Sacaan AI, Snell LD, Borosky S, Jones BE, Johnson KM, Balster RL, Burchett K, Kawasaki K, Hoch DB, Dingledine R (1989) Pharmacological profile of NPC-12626, a novel, competitive N-methyl-D-aspartate receptor antagonist. J Pharmacol Exp Ther 250: 100–109

    Google Scholar 

  • Foster AC, Gill R, Woodruff GN (1988) Neuroprotective effects of MK-801 in vivo: selectivity and evidence for delayed degeneration mediated by NMDA receptor activation. J Neurosci 8: 4745–4754

    Google Scholar 

  • Greenamyre JT, Young AB (1989) Excitatory amino acids and Alzheimer's disease. Neurobiol Aging 10: 593–602

    Google Scholar 

  • Grudt TJ, Jahr CE (1990) Quisqualate activates N-methyl-D-aspartate receptor channels in hippocampal neurons maintained in culture. Mol Pharmacol 37: 477–481

    Google Scholar 

  • Leander JD, Lawson RR, Ornstein PL, Zimmermann DM (1988) N-Methyl-D-aspartic acid-induced lethality in mice: selective antagonism by phencyclidine-like drugs. Brain Res 448: 115–120

    Google Scholar 

  • Lehmann J, Hutchison AJ, McPherson SE, Mondadori C, Schmutz M, Sinton CM, Tsai C, Murphy De, Steel DJ, Williams M, Cheney DL, Wood PL (1988) CGS19755, a selective and competitive N-methyl-D-aspartate-type excitatory amino acid receptor antagonist. J Pharmacol Exp Ther 246: 65–75

    Google Scholar 

  • Lehmann J, Schneider J, McPherson S, Murphy DE, Bernard P, Tsai C, Bennett DA, Pastor G, Steel DJ, Boehm C, Cheney DL, Liebman JM, Williams M, Wood PL (1987) CPP, a selective N-methyl-D-aspartate (NMDA)-type receptor antagonist: characerization in vitro and in vivo. J Pharmacol Exp Ther 240: 737–746

    Google Scholar 

  • Lodge D, Johnson KM (1990) Noncompetitive excitatory amino acid receptor antagonists. Trends Pharmacol Sci 11: 81–86

    Google Scholar 

  • Meldrum B, Garthwaite J (1990) Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 11: 379–387

    Google Scholar 

  • Monaghan DT, Bridges RJ, Cotman CW (1989) The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol 29: 365–402

    Google Scholar 

  • Murphy DE, Hutchison AJ, Hurt SD, Williams M, Sills MA (1988) Characterization of the binding of [3H]-CGS1977: a novel N-methyl-D-aspartate antagonist with nanomolar affinity in rat brain. Br J Pharmacol 95: 932–938

    Google Scholar 

  • Nielson EO, Madsen U, Schaumburg K, Brehm L, Kroggsgaard-Larsen P (1986) Studies on receptor-active conformations of excitatory amino acid agonists and antagonists. Eur J Med Chem-Chim Ther 21: 433–437

    Google Scholar 

  • Ornstein PL (1990) Excitatory amino acid receptor antagonists. US patent 4902695

  • Ornstein PL, Schoepp DD, Leander JD, Wong DT, Zimmerman DM, Lodge D (1990) LY233053: a structurally novel, potent and selective competitive N-methyl-D-aspartate receptor antagonist. In: Meldrum BS, Williams M (eds) Current and future trends in anticonvulsant, anxiety, and stroke therapy. Wiley-Liss, New York, pp 429–433

    Google Scholar 

  • Randolph LK, Ciminera JL (1975) Statistics. In: Osol A, Hoover JE (eds) Remington's pharmaceutical sciences, 15th edn. Mack Publishing Company, Easton, pp 117–150

    Google Scholar 

  • Schoepp DD, Azzaro AJ (1983) Effects of intrastriatal kainic acid injection on [3H]dopamine metabolism in rat striatal slices: evidence for postsynaptic glial cell metabolism by both the type A and B forms of monoamine oxidase. J Neurochem 40: 1340–1348

    Google Scholar 

  • Schoepp DD, Salhoff CR, Hillman CC, Ornstein PL (1989) CGS-19755 and MK-801 selectivity prevent rat striatal cholinergic and GABAergic neuronal degeneration induced by N-methyl-D-aspartate and ibotenate in vivo. J Neural Transm 78: 183–192

    Google Scholar 

  • Schoepp DD, Gamble AY, Salhoff CR, Johnson BG, Ornstein PL (1990a) Excitatory amino acid-induced convulsions in neonatal rats mediated by distinct receptor subtypes. Eur J Pharmacol 182: 421–427

    Google Scholar 

  • Schoepp DD, Ornstein PL, Leander JD, Lodge D, Salhoff CR, Zeman S, Zimmerman DM (1990b) Pharmacological characterization of LY233053: a structurally novel tetrazole-substituted competitive NMDA antagonist with a short duration of action. J Pharmacol Exp Ther 255: 1301–1308

    Google Scholar 

  • Simon JR, Contrera JF, Kuhar MJ (1976) Binding of [3H]kainic acid, an analogue of L-glutamate, to brain membranes. J Neurochem 26: 141–147

    Google Scholar 

  • Watkins JC, Krogsgaard-Larsen P, Honore T (1990) Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. Trends Pharmacol Sci 11: 25–33

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schoepp, D.D., Ornstein, P.L., Salhoff, C.R. et al. Neuroprotectant effects of LY 274614, a structurally novel systemically active competitive NMDA receptor antagonist. J. Neural Transmission 85, 131–143 (1991). https://doi.org/10.1007/BF01244705

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01244705

Keywords

Navigation